In this online CME self-learning program:
End-stage renal disease (ESRD) has been increasing in prevalence over recent years, due in part to higher rates of obesity and diabetes. ESRD necessitates one of two major treatment options: chronic dialysis or kidney transplantation, with dialysis often acting as a bridge to transplantation. Treatment of ESRD represents an enormous burden to the healthcare system, costing the Medicare system approximately $26.8 billion in 2008. Dialysis can also impinge significantly upon a patient’s quality of life.
The first kidney transplant was successfully completed in 1954, and it has now become the most common solid organ transplant surgery performed. Induction immunosuppressive therapy involves the use of biologic agents administered prior to and for a relatively short time following transplant. Guidelines from the Kidney Disease: Improving Global Outcomes (KDIGO) group provide recommendations for which agents should be used first- and second-line, but there is a significant variability in prescribing practices. These differences in practice suggest the presence of a practice gap between clinical practice and the recommendations put forward by the KDIGO.
This program has been designed to bring healthcare professionals’ knowledge of the rationale behind treatment and prevention of kidney transplant rejection up to date.
Healthcare professionals specializing in solid organ transplant surgery, transplant medicine, immunosuppression, and other providers who commonly encounter patients who have undergone kidney transplantation
This program is supported by educational grants from Novartis.
Release Date: December 10, 2012 -- Expiration Date: December 10, 2014
Faculty: Renu Nathan, PharmD, BCPS
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As an provider of continuing medical education, it is the policy of the ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is our policy to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Faculty Disclosure: Reenu Nathan, PharmD discloses that she has no relevant financial disclosures.
Disclosures of Educational Planner: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC. ScientiaCME has received grants from Novartis, the commercial supporter of this program.
Commercial Support Disclosure: This program is supported by educational grants from Novartis.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.